Front > HEALTHCARE

HEALTHCARE

Architects chosen for new Negev hospital

The winning firm is Rubinstein Ofer with Canadian architects Tye Farrow.

Michal Tsur at the Isreal Business Conference  credit: Cadya Levy "The best Parkinson's medication will be Israeli, and hybrid"

Remepy co-founder Michal Tsur told the Israel Business Conference about the therapy revolution whose time has come.

Teva CEO Richard Francis  credit: Teva spokesperson Teva divests from Japanese JV with Takeda

The Israeli pharmaceutical firm is selling its 51% stake in the joint venture to private equity firm J-Will Partners.

Asaf Danziger credit: PR Trial success boosts NovoCure

The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.

Nvidia offices in Yokneam credit: Nvidia Nvidia, Weizmann Inst., Pheno.ai develop glucose monitoring model

They have developed GluFormer, an AI model that can predict an individual’s future glucose levels and other health metrics based on past glucose monitoring data.

Elevance Health Israeli development center head Udi Goori  credit: PR US health insurance co Elevance closing Israeli center

The reason for the closure is probably to do with problems at the US health insurance giant itself, which has seen its share price fall 15% in the past month.

Reichman Medical School teaching laboratory credit: Rami Sinai Medical School approved for Reichman University

80 medical students will be enrolled in the first four-year program, which will begin in February 2025. Annual fees are NIS 90,000.

Teva's R&D labs in Netanya  credit: Teva PR Can Teva sustain its comeback?

Analysts are bullish on Teva, which is once again Israel's most valuable company, due to an improved US generics price environment and promising branded drug pipeline.

Teva CEO Richard Francis credit: Sivan Faraj Teva reports seventh straight quarter of growth

The Israeli pharmaceutical company beat the analysts and has again raised 2024 revenue guidance, this time to $16.1-16.5 billion.

British ambassador to Israel Simon Walters  credit: FCDO/British Embassy Israel New initiative connects Israeli tech to UK healthcare

The Dangoor Health-Tech Academy will foster collaboration between Israeli startups and Britain's National Health System, initially focusing on AI or automation-driven healthcare solutions.

Innoventric lead team credit: Eyal Toueg Israeli heart medical device co Innoventric raises $28.5m

The company has developed a device for the treatment of transcatheter tricuspid regurgitation (TR) using a revolutionary cross-caval technology.

Teva drug Copaxone  credit: Tamar Matsafi Teva shareholder sues after $450m US settlement

Avraham Barak alleges that Teva's board and officers must have approved the criminal activity that led to the penalty.

Teva's R&D labs in Netanya  credit: Teva PR Teva settles further price-fixing lawsuits in the US

Teva will pay a total of $450 million over six years to settle the cases.

SipNose credit: SipNose Aptar Pharma buys Israeli drug delivery co SipNose

The Yokneam based company has developed a nasal drug delivery system to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.

Nym Health team credit: Hagar Badar Israeli medical coding solutions co Nym raises $47m

Nym has automated the entire US healthcare medical coding process to deliver a faster, more cost-effective solution that outperforms traditional manual coding.

Immunai CEO Noam Solomon  credit: Immunai Israel's Immunai expands strategic tie with AstraZeneca

The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient.

Teva's R&D labs in Netanya  credit: Teva PR Teva settles opioid suits in Israel

Under the settlement, Teva's insurance company, which as far as is known is not Israeli, will pay the pharmaceutical company $40 million to fully close all potential claims.

Dr. Shimon Eckhouse  credit: Tomer Shalom FDA approval boosts weight loss pill co Epitomee

Epitomee's product expands in the stomach, giving a sense of satiety. The big challenge now will be marketing.

Discure CEO Yuval Mandelbaum credit: Discure Bioelectronic implantable device co Discure raises $16m

The Israeli company has developed a device for the treatment of degenerative disc diseaseõ

Level Ex founder and CEO Sam Glassenberg credit: Level Ex "Israel can be in the forefront of medical gaming"

Level Ex founder and CEO Sam Glassenberg tells "Globes" about the growing industry of medical video games and apps to train and improve the performance of doctors.

Healthcare credit: Tali Bogdanovsky, Shlomi Yosef Chemomab jumps on positive liver scarring trial results

Chemomab Therapeutics is developing a treatment for rare liver scarring disease PSC.

Johnson & Johnson credit: PR Johnson & Johnson buys Israeli co V-Wave for up to $1.7b

V-Wave’s shunt is an implantable device designed to decrease elevated left atrial pressure seen in congestive heart failure.

DatTwo app credit: DayTwo Microbiome personalized health co DayTwo shuts down

Ultimately the Israeli company’s platform was not distinct enough from other nutritional menus.

Richard Francis  credit: PR Teva reports strong Q2 results, raises 2024 forecast

Teva CEO: We are also showing significant progress in on our late-stage innovative pipeline.

MedicannX aeroponic cultivation of cannabis credit: MedicannX Medical cannabis co MedicannX raises NIS 70m

The company is investing in a production plant in Tirat Hacarmel, using innovative aeroponic cultivation technology.

Heart surgery credit: Shutterstock Israeli heart pump co Magenta Medical raises $105m

The company has developed a miniature heart pump that can be inserted into the body through minimally invasive surgery.

CytoReason cofounder and CEO David Harel credit: Geva Talmor Israeli AI disease models co CytoReason raises $80m

Six of the world’s top 10 pharma companies use CytoReason’s technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism, and other therapeutic areas.

Pof. Ehud Raanani   credit: Sheba Medical Center The heart surgeon with a $300m exit: We had glitches

The sale to Edwards Lifesciences vindicates Innovalve's solution for the most common, and most challenging, heart valve disorder, and also Sheba Hospital's innovation model.

Ofer Gonen credit: Eran Lavi MediWound raises $25m, acquisition still possible

Swedish company Mölnlycke Health Care, an international leader in the field of treating wounds, led the private placement.

Prof. Ehud Raanani credit: Sheba Edwards Lifesciences buys Israeli co Innovalve Bio Medical

Sources estimate that Edwards will pay more than $300 million for Innovalve's trans-catheter mitral valve replacement device.

Twitter Facebook Linkedin RSS Newsletters âìåáñ Israel Business Conference 2018